Myriad Genetics | MYGN - Cash And Equivalent


Myriad Genetics reported $124.4M in Cash and Equivalent for its fiscal quarter ending in March of 2026.





Cash And Equivalent Change Date
Agilent USD 1.81B 49M Mar/2026
Becton, Dickinson and Co. USD 813M 73M Mar/2026
Bio-Rad Laboratories USD 507.2M 22.6M Mar/2026
Bruker USD 133.4M 165.4M Mar/2026
Danaher USD 5.7B 1.09B Mar/2026
Illumina USD 1.42B 368M Dec/2025
J&J USD 21.69B 1.98B Mar/2026
Mettler Toledo International USD 66.89M 2.18M Dec/2025
Myriad Genetics USD 124.4M 25.2M Mar/2026
OraSure Technologies USD 176.96M 22.31M Mar/2026
Pacific Biosciences Of California USD 56.27M 223.23M Mar/2026
Quest Diagnostics USD 393M 27M Mar/2026
Quidel USD 140.4M 29.4M Mar/2026
Repligen USD 582.65M 16.63M Mar/2026
Revvity USD 860.32M 59.54M Mar/2026
Standard Biotools USD 265.77M 147.56M Mar/2026
Thermo Fisher Scientific USD 3.25B 6.6B Mar/2026
Veracyte USD 263.14M 99.44M Mar/2026
Waters USD 462M 125.83M Mar/2026